BMP10

Across TCGA pan-cancer cohorts, BMP10 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BMP10 data layer compared with 13 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher BMP10 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated BMP10 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

OV, LIHC, and STAD are the cancer types where BMP10 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.142	0.541	.002	12	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
STAD	DFS	Median	II,III,IV	1.000	0.377	.037	9	view →
LGG	DFS	Median	All	0.095	0.829	<.001	4	view →
MESO	OS	Median	All	0.169	0.556	.043	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

BMP10–OV (DFS)

Open the OV breakdown →